The deal, which is being funded by Merck, ParAllele will use its SNP-genotyping technology to "characterize the genetic changes in tumor samples" identified by the US-based drug maker.
Details of the agreement were not disclosed.
This is at least the second such collaboration for the companies. Almost exactly two years ago, ParAllele said it would use its lab-in-a-tube technology to develop assays, perform multiplexed genotyping, and provide data analysis for Merck.